[1]杨凡慧,陈跃,张春银.131I治疗青少年及儿童格雷夫斯甲亢的临床应用随访研究[J].国际放射医学核医学杂志,2017,41(2):98-102.[doi:10.3760/cma.j.issn.1673-4114.2017.02.004]
　Yang Fanhui,Chen Yue,Zhang Chunyin.Follow-up study on children and adolescents with Graves hyperthyroidism after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):98-102.[doi:10.3760/cma.j.issn.1673-4114.2017.02.004]
点击复制

131I治疗青少年及儿童格雷夫斯甲亢的临床应用随访研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第2期
页码:
98-102
栏目:
论著
出版日期:
2017-03-25

文章信息/Info

Title:
Follow-up study on children and adolescents with Graves hyperthyroidism after 131I treatment
作者:
杨凡慧1;  陈跃2;  张春银2
1. 637000 南充, 川北医学院附属医院核医学科;
2. 646000 泸州, 西南医科大学附属医院核医学科
Author(s):
Yang Fanhui1;  Chen Yue2;  Zhang Chunyin2
1. Department of Nuclear Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China;
2. Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
关键词:
格雷夫斯病; 青少年; 儿童; 近距离放射疗法; 碘放射性同位素
Keywords:
Graves disease; Adolescent; Child; Brachytherapy; Iodine radioisotopes
DOI:
10.3760/cma.j.issn.1673-4114.2017.02.004
摘要:
目的 探讨131I治疗青少年及儿童格雷夫斯甲状腺功能亢进症（Graves甲亢）的疗效及安全性。方法 89例青少年及儿童Graves甲亢患者行131I治疗。给药剂量采用公式法计算（2.59~4.44 MBq/g），参考病程、甲状腺质量和最高摄碘率进行修正。均采用一次性空腹口服，有合并症的给予相应处理。治疗后3、6、12个月随访，以后每年随访1次。前瞻性随访观察所有患者131I治疗后的治愈率、甲减率、甲状腺良恶性肿瘤发生情况、生长发育情况及后代健康情况。结果 随访至今的患者共80例，失访9例（10.1%）。131I治疗剂量范围为177.6~555.0 MBq，平均剂量为203.5 MBq。随访至12个月，131I治疗青少年及儿童Graves甲亢痊愈率82.50%，有效率98.75%，无效率1.25%；随着时间的推移甲减发生率逐渐升高，15年甲减累计发生率为35%。所有治疗患者生长发育均正常，均育有后代，后代智力及发育均正常。随访病例中无甲状腺癌、白血病等疾病发生。结论 131I治疗青少年及儿童Graves甲亢安全且疗效好，不良反应少，值得临床推广应用。
Abstract:
Objective To investigate the therapeutic effects and safety of 131I treatment on children and adolescents with Graves disease. Methods In this study, 89 children and adolescents with Graves hyperthyroidism cases were treated using 131I. 131I was given at a dosage of 2.59 to 4.44 MBq per gram of thyroid tissue and calibrated according to the course of disease, thyroid weight, and the highest iodine rate. The treatment was via oral medication on an empty stomach once a day. All cases were required to undergo a proper medical follow-up at the end of 3, 6, and 12 months after treatment and once a year later. The cure, hypothyroidism rates and incidence rates of benign and malignant thyroid tumors and the health of their offspring were studied. The safety of radioiodine treatment for children and adolescents’growth, development were also evaluated. Results Follow-up was conducted on 80 cases, with 30 males and 50 females, aged from 6 to 19(12.2±2.3) years; nine patients were lost to follow-up(10.1%). The maximum dose of 131I ranged from 177.6 to 555 MBq per patient; the mean dose was 203.5 MBq. After one year of radioiodine treatment, the cure rate was 82.50%, and the effective rate was 98.75%; no efficiency is very low(1.25%). As time passed, the incidence of hypothyroidism increased, reaching 35% within 15 years. All cured patients had normal growth and produced offspring whose intelligence and development were normal. No one was diagnosed with thyroid carcinoma or leukemia in his/her medical follow-ups. Conclusions Using 131I for treating children and adolescents with Graves hyperthyroidism was effective and safe. The minimal side effects make it worthy of wide application in clinics.

参考文献/References:

[1] Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J]. Thyroid, 2011, 21(6):593-646. DOI:10. 1089/thy. 2010. 0417.
[2] 潘中允. 实用核医学[M]. 北京:人民卫生出版社, 2014:177. Pan ZY. Practice of nuclear medicine[M]. Beijing:People’s Medical Publishing House, 2014:177.
[3] Lavard L, Ranlov I, Perrild H, et al. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study[J]. Eur J Endocrinol, 1994, 130(6):565-568.
[4] Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood:a National population based study in the UK and Ireland[J]. Clin Endocrinol(Oxf), 2010, 72(3):358-363. DOI:10. 1111/j. 1365-2265. 2009. 03717. x.
[5] Ohye H, Minagawa A, Noh JY, et al. Antithyroid drug treatment for graves’ disease in children:a long-term retrospective study at a single institution[J]. Thyroid, 2014, 24(2):200-207. DOI:10. 1089/thy. 2012. 0612.
[6] Rivkees SA. Pediatric graves’ disease:controversies in management[J]. Horm Res Paediatr, 2010, 74(5):305-311. DOI:10. 1159/000320028.
[7] 谭天秩. 临床核医学[M]. 2版. 北京:人民卫生出版社, 2003:1224. Tan TZ. Clinice of nuclear medicine[M]. 2nd ed. Beijing:People’s Medical Publishing House, 2003:1224.
[8] 陈丹云, 陈棠华. 131I与抗甲状腺药物治疗儿童Graves病的疗效对照研究[J]. 中华儿科杂志, 2005, 43(7):507-509. DOI:10. 3760/j. issn:0578-1310. 2005. 07. 007. Chen DY, Chen TH. Comparison of efficacy of 131I and antithyroid drugs in the treatment of Graves’ disease in children[J]. Chin J Pediatr, 2005, 43(7):507-509.
[9] Ma C, Kuang A, Xie J, et al. Radioiodine treatment for pediatric Graves’ disease[J/OL]. Cochrane Database Syst Rev, 2008(3):CD006294[2016-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/18646146. DOI:10. 1002/14651858. CD006294. pub2.
[10] 郑艳, 赵德善, 付松海, 等. 儿童和青少年Graves甲亢患者131I治疗剂量的分析研究[J]. 国际放射医学核医学杂志, 2013, 37(2):69-73. Zheng Y, Zhao DS, Fu SH, et al. The dose analysis of 131I treatment in pediatric patients with Graves hyperthyroidism[J]. Int J Radiat Med Nucl Med, 2013, 37(2):69-73. DOI:10. 3760/cma. j. issn. 1673-4114. 2013. 02. 002.
[11] Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive Iodine in treating young Graves’ patients[J]. J Clin Endocrinol Metab, 2004, 89(9):4229-4233. DOI:10. 1210/jc. 2003-031223.
[12] West JD, Cheetham TD, Dane C, et al. Should radioiodine be the first-line treatment for paediatric Graves’ disease?[J]. J Pediatr Endocrinol Metab, 2015, 28(7/8):797-804. DOI:10. 1515/jpem-2014-0176.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[6]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[7]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[8]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
　Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[9]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
　WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[10]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[11]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[12]牟联超,李先映,石彩虹.131I治疗青少年Graves病58例临床分析[J].国际放射医学核医学杂志,2010,34(5):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
　MU Lian-chao,LI Xian-ying,SHI Cai-hong.Analyze of 131I therapy on 58 youngsters with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
[13]李佳,秦岚,任众,等.131I治疗青少年Graves病的量效分析[J].国际放射医学核医学杂志,2010,34(3):152.
　LI Jia,QIN Lan,REN Zhong,et al.An analysis of the dose and the therapeutic effect of 131I in treating youngsters with Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):152.

备注/Memo

备注/Memo:
收稿日期:2016-11-21。
通讯作者:张春银,Email:zhangchunyin345@sina.com
更新日期/Last Update: 2017-04-24